EVAXION A/S (EVAX) Stock Overview
USA - NASDAQ:EVAX - US29970R3030 - ADR
EVAX Key Statistics, Chart & Performance
The current stock price of EVAX is 5.95 USD. In the past month the price increased by 29.5%. In the past year, price decreased by -55.6%.
EVAX Latest News, Press Relases and Analysis
EVAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.56 | 403.41B | ||
| AMGN | AMGEN INC | 13.4 | 157.37B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 148.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.82 | 107.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.66 | 69.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.45B | ||
| ARGX | ARGENX SE - ADR | 88.73 | 50.31B | ||
| INSM | INSMED INC | N/A | 39.79B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 34.01B | ||
| NTRA | NATERA INC | N/A | 26.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.41B | ||
| BIIB | BIOGEN INC | 9.48 | 22.24B |
Related stock screener links
About EVAX
Company Profile
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Company Info
EVAXION A/S
Dr. Neergaards Vej 5F
Hoersholm 1260 DK
CEO: Lars Staal Webner
Employees: 46
EVAXION A/S / EVAX FAQ
Can you describe the business of EVAXION A/S?
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
What is the stock price of EVAXION A/S today?
The current stock price of EVAX is 5.95 USD. The price increased by 3.48% in the last trading session.
What is the dividend status of EVAXION A/S?
EVAX does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVAX stock?
EVAX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in EVAXION A/S be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EVAX.
Can you provide the number of employees for EVAXION A/S?
EVAXION A/S (EVAX) currently has 46 employees.
What is the Short Interest ratio of EVAXION A/S (EVAX) stock?
The outstanding short interest for EVAXION A/S (EVAX) is 8.85% of its float.
EVAX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EVAX. When comparing the yearly performance of all stocks, EVAX is one of the better performing stocks in the market, outperforming 86.14% of all stocks.
EVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVAX. EVAX has a bad profitability rating. Also its financial health evaluation is rather negative.
EVAX Financial Highlights
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS increased by 76.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.34% | ||
| ROE | -192.34% | ||
| Debt/Equity | 1.73 |
EVAX Forecast & Estimates
8 analysts have analysed EVAX and the average price target is 13.77 USD. This implies a price increase of 131.43% is expected in the next year compared to the current price of 5.95.
For the next year, analysts expect an EPS growth of 23.5% and a revenue growth 14.94% for EVAX